Ramucirumab plus Docetaxel Improves Progression-free survival in Urothelial Cancer

Newswise imageRamucirumab plus docetaxel improves progression-free survival in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy, according to late-breaking results from the phase III RANGE trial presented today at the ESMO 2017 Congress in Madrid (1) to be published in The Lancet (2).